Back to Journals » OncoTargets and Therapy » Volume 11

Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy

Authors Zhang Y, Li Z, Zhang W, Chen W, Song Y

Received 7 January 2018

Accepted for publication 7 March 2018

Published 23 April 2018 Volume 2018:11 Pages 2311—2317

DOI https://doi.org/10.2147/OTT.S161803

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Yao Dai


Yang Zhang,1,* Zongjuan Li,2,* Wei Zhang,1,* Wei Chen,1 Yipeng Song1

1Department of Radiation Oncology, Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital, Yantai, Shandong, People’s Republic of China; 2Department of Radiation Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China

*These authors contributed equally to this work

Background: This study aimed to investigate risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy.
Subjects and methods: The study prospectively enrolled 212 esophageal carcinoma patients undergoing chemoradiotherapy and evaluated 16 clinical parameters. The best cut-off values were determined by receiver operating characteristics curves. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated by the Cox proportional hazards model. Kaplan–Meier analysis was used to evaluate the cumulative probability.
Results: In total, 22 patients (10.38%) developed esophageal fistula, of whom 9 experienced fistula during treatment and the other 13 patients developed fistula after chemoradiotherapy. The median time until occurrence was 5.75 months (range 0.6–8 months). In univariate analysis, the evaluated significant factors were Karnofsky performance status, smoking status, esophageal stenosis, T stage, fraction dose, and carcinoembryonic antigen (CEA). In addition, esophageal stenosis (HR=4.089, 95% CI 1.451–11.527, p=0.008), T stage (HR=2.663, 95% CI 1.019–6.960, p=0.046), and CEA (HR=0.309, 95% CI 0.124–0.768, p=0.011) were revealed as risk parameters in further multivariate analysis.
Conclusion: This is the first prospective study to evaluate factors associated with fistula formation in patients with esophageal carcinoma receiving chemoradiotherapy. More attention should be given to patients with esophageal stenosis, stage T4 disease, and high levels of CEA.

Keywords: esophageal fistula, esophageal carcinoma, chemoradiotherapy, side effect, risk factors
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]